Provenge (sipuleucel-T), Dendreon corporation-manufactured prior to the metastatic tumor prostate cancer patients for new treatment therapy. Treatment of United States food and Drug Administration 12 manufacturing facilities in New Jersey by allowing you to work last April 29, 2010 is approved. 2010 Clinical Oncology Genitourinary of United States society annual meeting doctor Philip Kantoff said research first big control clinical trials showed the lives of cancer patients to prolong the immune system-based treatment is assumed. Recently, Dendreon's 36 manufacturing facilities in New Jersey in April 2010 was already approved manufacturing facilities 12 support Provenge production and distribution increase company to allow the United States was approved by the FDA.
Provenge cellular immunotherapy and Prostate Tumor Antigen target prostate tumor growth delay's blood type. This type of immunotherapy dictionary and recurrent prostate cancer hormone therapy as well as other treatment modalities in the resistant patient prognosis and quality of life has been designed to improve. This treatment in patients with metastatic prostate cancer survival rate is believed to extend it. Dr. Daniel George, Genitourinary Oncology according to the Director of the Provenge is the most significant symptoms not survival in asymptomatic patients benefited or at least symptoms metastatic prostate cancer.
Provenge treatment the patient's white blood cells by collecting with the work known as prostate acid phosphatase prostate specific antigen in the exposure. These cells in prostate cancer patients are injected again when designed to attack the antigen is incubated with. It is in the patient's body, attacked Antigen and destroy cancer cells, the immune system. This therapy prostate acid phosphatase (PAP); for immune response is designed to encourage. Most antigens expressed in prostate cancer. Provenge therapy used cellular immunotherapy; therapies belonging to a new class of the first of it's use of each patient's white blood cell therapy is the treatment of aligned type. Dana Farber Cancer Institute Provenge treatment according to a survey the patient become part of their immune system against cancer treatment arsenal marks the beginning of a new era.
Male hormone therapy responding who and who is metastatic prostate cancer, as well as little or no cancer-related pain efficient institutions working experience patient treatment candidates. Provenge is a person's vein blood vessels through the injection is administered through. Having two weeks range interval is specified in three doses. Advanced metastatic prostate cancer 512 patients as well as hormone treatment has patients resistant to 3 trial cancer treatment centre in phase clinical research. Randomly, the patient is given an inactive placebo with Provenge. Placebo pills, compared to patients receiving Provenge 4.1 months average survival of patients by expanding and 22.5% of the total mortality rate was reduced to. According to Dr. Mitchell gold, the average survival benefit demonstrated metastatic castration-resistant Provenge prostate cancer treatment in a representation of a major milestone is an important 4.1 months President of Dendreon Corporation.
Safety during the evaluation of common negative response received to see Provenge treatment or leukapheresis (extract and white blood cells of incubation) 601 patient procedure again fatigue, chills, fever, pain, nausea, headaches and joint pain. Important adverse reactions include acute infusion reaction and receiving Provenge cerebrovascular events such as has been reported in stroke patient. Signs of infusion reaction, chills, breathing, dizziness, high blood pressure and difficulty, vomiting. Most of the severity of adverse reactions, and mild on the right.
Dr. David Penson, Vanderbilt University Medical Center, Professor of Urologic Surgery Provenge approval according to men's advanced prostate cancer treatment represents a significant development. Provenge is now available for some processing options: new therapy of choice. "The first used cellular immunotherapy, represents the approved Provenge prostate cancer treatment for new important science and clinical development" Philip Kantoff, doctors, and solid tumor Oncology, Department of the Chief of the clinical investigator Dana Farber Cancer Institute, Professor of medicine at the Harvard senior said.
Ul Urieash has to offer for people with prostate cancer, and related information who is prostate cancer health professionals. Prostate cancerfor more information visit their site.
Tidak ada komentar:
Posting Komentar